Navigation Links
Vasogen Announces First Quarter 2009 Results
Date:4/13/2009

assets. The process has also included a review of the potential out-licensing of assets, lapsing of patents and patent applications, asset divestiture, or liquidation of the Company. At this time, we have significantly narrowed down the number of third party proposals under consideration. If a definitive agreement that the Board believes is in the best interest of our shareholders cannot be reached in the near future, the Board will consider the other alternatives that it has also been evaluating. These alternatives include the potential to realize value from the monetization of certain intangible assets either alone or potentially in combination with a strategic transaction. The Board will continue to assess the merits of these options relative to liquidating the Company and distributing the remaining cash to the shareholders. - As at February 28, 2009, we had cash and cash equivalents of $7.3 million and had 22.5 million common shares issued and outstanding. Other than our accounts payable and accrued liabilities, we do not have any debt. - We sold a United States patent application and its related foreign counterparts for US$0.4 million. This device-based intellectual property has not been used to date in the Celacade System; however, we have retained rights to this technology for any potential use as it relates to our Celacade System. - Subsequent to quarter end, on March 25, 2009, the NASDAQ Stock Market further suspended the enforcement of the Minimum Bid Price Rule requiring a minimum US$1.00 closing price until July 20, 2009. Accordingly, the NASDAQ indicated that it will not take action to delist any security, including our common shares, for a violation of the minimum bid price rule during the suspension. '/>"/>
SOURCE Vasogen Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Vasogen Announces 2008 Year-End Results
2. Vasogen Announces Sale of Patent Application and Provides Corporate Update
3. Vasogen Complies with NASDAQ Marketplace Rule 4350(c)(1)
4. Vasogen Provides Corporate Update
5. Vasogen Announces Third Quarter 2008 Results
6. Vasogen Announces Second Quarter 2008 Results
7. Vasogen Provides Corporate Update
8. Vasogen to Webcast Presentation at the Rodman & Renshaw 5th Annual Global Healthcare Conference
9. Vasogen Receives NASDAQ Notification Related to Minimum Bid Price
10. Vasogen Announces Implementation of Strategic Restructuring Plan
11. Vasogen Announces First Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... disease risks, the biological characteristics people care most about ... heightthe textbook example of a complex traitattributes like risk ... genetic and environmental influences, making it challenging to find ... typically mate two individuals that differ in key waysfor ... study their descendents, looking for genes that tend to ...
(Date:9/19/2014)... YORK , Sept. 19, 2014  An entire ... forms of inherited neuropathies – Charcot-Marie-Tooth disease (CMT) – ... and legs, causing extreme muscle atrophy, weakness, and foot ... the US and millions worldwide. CMT is a progressive ... of their legs, requiring mobility devices such as leg ...
(Date:9/19/2014)... Florida , September 19, 2014 ... release latest developments, patents and results of studies and ... Eli Lilly and Company (NYSE: LLY ), ... Corporation (NASDAQ: CELG ) and Arena Pharmaceuticals ... a leader in developing prodrug therapeutics for the treatment ...
(Date:9/19/2014)... ROCKLAND, Massachusetts , September 19, 2014 ... with the 53rd European Society for Paediatric Endocrinology (ESPE) ... advancement of science and medical research in the field ... of Merck KGaA, Darmstadt, Germany , ... Growth Innovation (GGI) for 2014. The awards were announced ...
Breaking Biology Technology:Want to link genes to complex traits? Start with more diversity 2September is Charcot-Marie-Tooth (CMT) Awareness Month - Scheduled events, activities and important partnerships announced throughout the month! 2Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 2Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 3Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 4Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 5Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 6Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 7EMD Serono Awards Grant for Growth Innovation (GGI) for the First Time 2EMD Serono Awards Grant for Growth Innovation (GGI) for the First Time 3
... , CINCINNATI , June 3 Kendle ... organization (CRO), today announced it is ranked a top CRO ... Survey. Kendle is the only CRO to be ranked consistently ... four years in the annual U.S. and European site surveys ...
... June 3 Sangamo BioSciences, Inc. (Nasdaq: SGMO ) announced ... Wolff , executive vice president and CFO, will provide an update on the ... business strategy at two investor conferences during the month of June: , ... The Jefferies 2010 ...
... June 3 The John Theurer Cancer Center ... that will be presented at the American Society of Clinical ... – 8, 2010 in Chicago . Research highlights include ... lymphoma, the efficacy and safety of a new genetically engineered ...
Cached Biology Technology:Kendle Rated a Top CRO to Work with for Fourth Consecutive Year 2Kendle Rated a Top CRO to Work with for Fourth Consecutive Year 3Sangamo BioSciences Announces Presentation at Two Upcoming Investor Conferences 2New Cancer Treatments and Combination Therapies Presented by Leading Experts from the John Theurer Cancer Center at the American Society of Clinical Oncology Annual Meeting 2New Cancer Treatments and Combination Therapies Presented by Leading Experts from the John Theurer Cancer Center at the American Society of Clinical Oncology Annual Meeting 3New Cancer Treatments and Combination Therapies Presented by Leading Experts from the John Theurer Cancer Center at the American Society of Clinical Oncology Annual Meeting 4New Cancer Treatments and Combination Therapies Presented by Leading Experts from the John Theurer Cancer Center at the American Society of Clinical Oncology Annual Meeting 5New Cancer Treatments and Combination Therapies Presented by Leading Experts from the John Theurer Cancer Center at the American Society of Clinical Oncology Annual Meeting 6
(Date:9/21/2014)... Carbon dioxide emissions, the main contributor to global warming, are ... high of 40 billion tonnes. , The 2.5 per cent ... Global Carbon Project, which is co-led in the UK by ... the University of East Anglia and the College of Engineering, ... It comes ahead of the New York Climate Summit, where ...
(Date:9/21/2014)... recent years, new strains of bacteria have emerged that ... superbugs, including drug-resistant forms of tuberculosis and staphylococcus, infect ... least 23,000. Despite the urgent need for new treatments, ... in the past decade. , MIT engineers have now ... a gene-editing system that can disable any target gene, ...
(Date:9/21/2014)... MA -- Shellfish such as mussels and barnacles secrete ... or ship hulls, even underwater. Inspired by these natural ... materials that could be used to repair ships or ... their new waterproof adhesives, the MIT researchers engineered bacteria ... mussel proteins as well as a bacterial protein found ...
Breaking Biology News(10 mins):CO2 emissions set to reach new 40 billion ton record high in 2014 2CO2 emissions set to reach new 40 billion ton record high in 2014 3Battling superbugs 2Battling superbugs 3Battling superbugs 4Engineered proteins stick like glue -- even in water 2Engineered proteins stick like glue -- even in water 3
... (IUPAB) and Springer will launch the journal Biophysical ... is the new official journal of the IUPAB, ... societies with approximately 15,000 members. The entire IUPAB ... journal in order to demonstrate the close affiliation between ...
... football players who gain weight to add power to their ... diabetes and heart disease later in life, a new study ... and defensive linemen who underwent a battery of tests for ... at least three of five risk factors that indicate a ...
... flies snore, but rest assured that when you,re asleep ... January 2009 issue of the journal GENETICS ... City have shown that the circadian rhythms (sleep/wake cycles) ... of the same "cellular machinery" as that of humans. ...
Cached Biology News:Biophysical Reviews makes debut in 2009 2Athletes not spared from health risks of metabolic syndrome 2Athletes not spared from health risks of metabolic syndrome 3When it comes to sleep research, fruit flies and people make unlikely bedfellows 2
...
... robotic workstations is designed for laboratories with ... ideal automation platform for routine sample preparation ... improving throughput, process consistency and safety. ... allows you to control the robotic and ...
...
...
Biology Products: